Pharmaceutical Executive, Jul 1, 2004

Executive Profile

Think Small Grow Big

By Joanna Breitstein

After Adderall, what's next for Shire? CEO Matthew Emmens thinks the answer lies in a simple strategy.

Columns

Training During Transition

By John Kuchna

During the change phase, it is critical that communications in the field remain consistent and that customers perceive little or no disruption in the quality of the sales call.

Features

Pricing Climate Heats Up in US and Europe

By Neil Turner

In 2003, Big Pharma produced only a dozen new drugs. At the same time, it came under new pressure to create value from those thin pipelines. In that "hot squeeze" of a climate, pharma companies needed price premiums for every product in every market. They were more successful in some countries than in others. Other pricing trends also took their toll.

Stop Giving Away Your Secrets

By Michael D. Lam

Big pharma companies aggressively gather sensitive intelligence about their competitors, but few, strangely, make a systematic effort to protect their own.

One World, One Voice

By Bruno Delagneau, MD

Critics often claim that international marketing programs ignore fundamental differences that exist across countries and cultures.